Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Handl Therapeutics logo — Handl Therapeutics develops gene therapies for complex neuro...

Handl Therapeutics

Handl Therapeutics develops gene therapies for complex neurodegenerative diseases through academic and partner collaborations.

Founded 2019 Belgium Belgium Grant Total: $3.00M Biotechnology, Health Care +1

General Information

Company Name Handl Therapeutics
Founded Year 2019
Location Belgium Belgium
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Handl Therapeutics. To contact Handl Therapeutics, visit handltherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Handl Therapeutics compare?

A PDF of Handl Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Handl Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Handl Therapeutics

Handl Therapeutics is a biotechnology startup based in Belgium that is dedicated to developing cutting-edge gene therapies for complex neurodegenerative diseases. Established in 2019, the company's mission is to advance the treatment of these challenging conditions by harnessing the potential of disease-modifying in vivo gene therapy. This approach aims to make a significant impact in the healthcare industry by addressing unmet medical needs. The startup's slogan, "Handl Therapeutics develops gene therapies for complex neurodegenerative diseases through academic and partner collaborations," underscores its focus on collaboration and innovation. Handl Therapeutics operates with a highly integrative business model, leveraging strong relationships with international academic partners and close collaborations with industry peers to drive its therapeutic platform forward. In September 2020, Handl Therapeutics secured a noteworthy investment of €3.00M in the form of a grant from Agentschap Innoveren & Ondernemen. This investment serves as a testament to the confidence that reputable organizations place in the company's vision and potential. Handl Therapeutics' ability to attract financial support and partnerships is indicative of its promise in the biotechnology, healthcare, and pharmaceutical industries.

Business keywords: Gene Therapy, Neurodegenerative Diseases, Therapeutics, In Vivo Gene Therapy, Drug Development, Collaborations, Academic Partnerships, Medical Innovation, Healthcare Impact, Unmet Medical Needs

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €3.00M 1
Agentschap Innoveren & Ondernemen
15 Sep 2020

Handl Therapeutics Alternatives & Competitors

View All Alternatives
Handl Therapeutics vs
American Gene Technologies® International Inc.
American Gene Technologies® International Inc. United States

Our mission is to leverage the power of gene and cell therapy to reduce human suffering from serious...

Series F
26 employees
Biotechnology, Health Care
Handl Therapeutics vs
Angitia Biopharmaceuticals
Angitia Biopharmaceuticals United States

Developing innovative medicines to address serious musculoskeletal diseases

Series B
52 employees
Biopharma, Biotechnology
Handl Therapeutics vs
CORXEL Pharmaceuticals
CORXEL Pharmaceuticals China

Our mission is to develop innovative cardiometabolic therapies globally.

Series D
40 employees
Biotechnology, Health Care
View all alternatives

FAQ About Handl Therapeutics

Handl Therapeutics develops gene therapies for complex neurodegenerative diseases through academic and partner collaborations.
Handl Therapeutics was founded in 2019.
Handl Therapeutics is headquartered in Belgium.
Handl Therapeutics operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Gene Therapy, Neurodegenerative Diseases, Therapeutics and In Vivo Gene Therapy.
Handl Therapeutics has completed 1 funding round, raising a total of $3.00M. The latest funding stage is Grant.
Top alternatives and competitors to Handl Therapeutics include American Gene Technologies® International Inc., Angitia Biopharmaceuticals, CORXEL Pharmaceuticals, Amyl Therapeutics, Capstan Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Handl Therapeutics and American Gene Technologies® International Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Handl Therapeutics, https://bouncewatch.com/company/handl-therapeutics, updated 1 September 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout